tetano
Editor, Senior Moderator
Int J Pharm
. 2023 Apr 5;122921.
doi: 10.1016/j.ijpharm.2023.122921. Online ahead of print.
Functionalized protein microparticles targeting hACE2 as a novel preventive strategy for SARS-CoV-2 infection
Yujia Li[SUP] 1 [/SUP], Yike Huang[SUP] 1 [/SUP], Kehui Zhu[SUP] 1 [/SUP], Xiaoqiong Duan[SUP] 1 [/SUP], Shilin Li[SUP] 1 [/SUP], Min Xu[SUP] 1 [/SUP], Chunhui Yang[SUP] 1 [/SUP], Jiaxin Liu[SUP] 1 [/SUP], Hans Bäumler[SUP] 2 [/SUP], Pin Yu[SUP] 3 [/SUP], He Xie[SUP] 4 [/SUP], Bin Li[SUP] 5 [/SUP], Ye Cao[SUP] 6 [/SUP], Limin Chen[SUP] 7 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), resulting in a serious burden on public health and social economy worldwide. SARS-CoV-2 infection is mainly initialized in the nasopharyngeal cavity through the binding of viral spike (S) protein to human angiotensin-converting enzyme 2 (hACE2) receptors which are widely expressed in many human cells. Thus, blockade of the interaction between viral S protein and hACE2 receptor in the primary entry site is a promising prevention strategy for the management of COVID-19. Here we showed protein microparticles (PMPs) decorated with hACE2 could bind and neutralize SARS-CoV-2 S protein-expressing pseudovirus (PSV) and protect host cells from infection in vitro. In the hACE2 transgenic mouse model, administration of intranasal spray with hACE2-decorated PMPs markedly decreased the viral load of SARS-CoV-2 in the lungs though the inflammation was not attenuated significantly. Our results provided evidence for developing functionalized PMPs as a potential strategy for preventing emerging air-borne infectious pathogens, such as SARS-CoV-2 infection.
Keywords: SARS-CoV-2; hACE2; preventive strategy; protein microparticles.
. 2023 Apr 5;122921.
doi: 10.1016/j.ijpharm.2023.122921. Online ahead of print.
Functionalized protein microparticles targeting hACE2 as a novel preventive strategy for SARS-CoV-2 infection
Yujia Li[SUP] 1 [/SUP], Yike Huang[SUP] 1 [/SUP], Kehui Zhu[SUP] 1 [/SUP], Xiaoqiong Duan[SUP] 1 [/SUP], Shilin Li[SUP] 1 [/SUP], Min Xu[SUP] 1 [/SUP], Chunhui Yang[SUP] 1 [/SUP], Jiaxin Liu[SUP] 1 [/SUP], Hans Bäumler[SUP] 2 [/SUP], Pin Yu[SUP] 3 [/SUP], He Xie[SUP] 4 [/SUP], Bin Li[SUP] 5 [/SUP], Ye Cao[SUP] 6 [/SUP], Limin Chen[SUP] 7 [/SUP]
Affiliations
- PMID: 37028575
- DOI: 10.1016/j.ijpharm.2023.122921
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), resulting in a serious burden on public health and social economy worldwide. SARS-CoV-2 infection is mainly initialized in the nasopharyngeal cavity through the binding of viral spike (S) protein to human angiotensin-converting enzyme 2 (hACE2) receptors which are widely expressed in many human cells. Thus, blockade of the interaction between viral S protein and hACE2 receptor in the primary entry site is a promising prevention strategy for the management of COVID-19. Here we showed protein microparticles (PMPs) decorated with hACE2 could bind and neutralize SARS-CoV-2 S protein-expressing pseudovirus (PSV) and protect host cells from infection in vitro. In the hACE2 transgenic mouse model, administration of intranasal spray with hACE2-decorated PMPs markedly decreased the viral load of SARS-CoV-2 in the lungs though the inflammation was not attenuated significantly. Our results provided evidence for developing functionalized PMPs as a potential strategy for preventing emerging air-borne infectious pathogens, such as SARS-CoV-2 infection.
Keywords: SARS-CoV-2; hACE2; preventive strategy; protein microparticles.